\n
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t<\/p>\n\n\t\t\t\tNo approved vaccines or therapeutics\t\t\t<\/h2>\n<\/p><\/div>\n Unlike many previous Ebola outbreaks, which were attributable to the Zaire virus, this outbreak is attributable to the Bundibugyo virus, for which there aren’t any approved vaccines or therapeutics, Ghebreyesus said.<\/p>\n
\n
\n\t\t\t\t\t
\n\t\t\t\t<\/div>\n
\n
Get weekly health news<\/h2>\n Receive the most recent medical news and health information delivered to you each Sunday.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n
The Bundibugyo virus was first detected in Uganda\u2019s Bundibugyo district during a 2007-08 outbreak that infected 149 people and killed 37. The second time was in 2012, in an outbreak in Isiro, Congo, where 57 cases and 29 deaths were reported.<\/p>\n
\u201cYesterday, WHO convened the leaders of several partner organizations under the interim Medical Countermeasures Network, to review the pipeline of vaccines, therapeutics and diagnostics,\u201d Ghebreyesus added.<\/p>\n
The WHO R&D Blueprint has convened its technical advisory group on therapeutics and really helpful prioritizing two monoclonal antibodies to advance in clinical trials.<\/p>\n
\n
\n
\n\t\t\t\t\t
<\/p>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2:07<\/time>WHO head fears Ebola outbreak being underestimated<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t<\/span>
The advisory group really helpful the evaluation of the antiviral obeldesivir in a clinical trial as post-exposure prophylaxis for people who find themselves high-risk contacts, in keeping with Ghebreyesus.<\/p>\n
\n
Story continues below commercial<\/p>\n<\/p><\/div>\n
The clinical trial is now being developed jointly with Africa CDC and the Collaborative Open Research Consortium on filoviruses.<\/p>\n
The WHO can also be discussing with partners candidate vaccines in the event and manufacturing pipeline.<\/p>\n
Sylvie Briand, the WHO\u2019s chief scientist, said the organization is repurposing drugs previously used for various strains of Ebola viruses.<\/p>\n
\u201cWe make a listing of all of the things which might be potentially useful or within the pipeline after which the committee looks at prioritizing them using numerous criteria,\u201d she said. \u201cThe primary criteria is their safety. Then also we take a look at criteria for implementation. We will not be yet at this phase of criteria for implementation since the committee only checked out the drugs which might be available.\u201d<\/p>\n
Briand said the subsequent steps require discussing with health authorities and other partners to see how they’ll implement them.<\/p>\n
She called the antiviral obeldesivir a \u201cpromising treatment\u201d but it would must be implemented under a \u201cvery, very strict protocol.\u201d<\/p>\n
Vasee Moorthy, the WHO\u2019s senior science and strategy advisor, said the WHO already has \u201csomething prioritized within the prevention of cases and that\u2019s the oral obeldesivir that has already been mentioned.\u201d<\/p>\n
\n
\n\t\t\tMore on World<\/button>More videos<\/button>\n\t\t<\/p>\n<\/p><\/div>\nEarlier this week, Moorthy said one vaccine candidate was six to nine months away from being available for clinical trials.<\/p>\n
\n
Story continues below commercial<\/p>\n<\/p><\/div>\n
One other is being developed by the University of Oxford and India\u2019s Serum Institute and was having doses \u201cmanufactured as we speak,\u201d he added.<\/p>\n
But Moorthy said there was no data from animal testing to support the vaccine.<\/p>\n
\u201cIt is feasible that doses may very well be available for clinical trial in two to 3 months but there may be numerous uncertainty about whether that may be a promising candidate,\u201d he said.<\/p>\n
\u201cIt’ll rely upon the animal data on whether that\u2019s considered a promising candidate research vaccine for Bundibugyo, in order that\u2019s what I might say in regards to the pipeline now.\u201d<\/p>\n
\n
\n\t\t\t\t<\/span>\n\t\t\t\t\t\t<\/p>\n\n\t\t\t\tResidents burn Ebola treatment centre in Congo\t\t\t<\/h2>\n<\/p><\/div>\n The WHO head spoke in regards to the Ebola treatment centre in a town at the guts of the outbreak in eastern Congo that was set on fire Thursday.<\/p>\n
\n
Story continues below commercial<\/p>\n<\/p><\/div>\n
The arson attack in Rwampara took place after people were stopped from retrieving the body of a neighborhood man, in keeping with a senior police officer.<\/p>\n
The bodies of those that die from Ebola could be highly contagious and result in further spread when people prepare them for burial and gather for funerals. The damaging work of burying suspected victims is being managed wherever possible by authorities.<\/p>\n
Deputy Senior Commissioner Jean Claude Mukendi, head of the general public security department in Ituri Province, said the youths accused of setting the hearth had not understood the protocols for burying a suspected Ebola victim.<\/p>\n
![\"Click](\"https:\/\/i2.wp.com\/media.globalnews.ca\/videostatic\/news\/sugp9j3fji-xkcbin9317\/THU_EBOLA_SITE_THUMB_210526.jpg?w=1040&quality=70&strip=all\")